article thumbnail

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

Pharmaceutical Technology

If there is a quick agreement with an expectation for changes to be implemented around 2029, Olteanu says crucial investment decisions can be made while considering the Pharma Package as investment remains one of the key challenges holding Europe back from its dreams of global competitiveness.

article thumbnail

Big pharma braces for revenue headwinds as patent expiries loom

Pharmaceutical Technology

Other drugs are set to face competition too, with both MSD’s Keytruda (pembrolizumab) and Johnson & Johnson’s (J&J) Darzalex/Faspro (daratumumab and hyaluronidase-fihj) losing US exclusivity by 2029, representing a particular headwind in oncology. Give your business an edge with our leading industry insights.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Vor Bio back from brink with autoimmune drug deal rising to $4bn

Pharmaceutical Technology

For example, the rheumatoid arthritis drug market across the eight major global markets is forecast to reach $29.1bn by 2029, according to analysis by GlobalData. Sanofi’s blockbuster autoimmune drug Dupixent (dupilumab) is one of the best-selling drugs in the world, representing the lucrative nature of the sector.

article thumbnail

AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline

Pharmaceutical Technology

According to William Blair, forecast revenue rate from 2024 to 2029 growth rate for AbbVie trails only Eli Lilly and Sanofi, representing an “attractive opportunity” for long-term investors. We may still continue to send you service-related and other non-promotional communications. Sign up for our daily news round-up!

article thumbnail

Vetter breaks ground on $285m US clinical manufacturing site

Pharmaceutical Technology

The facility will be complete and ready for media fill by late 2029, with plans to move Vetter’s existing clinical operations in Skokie. The planned 160,000ft² facility will focus on aseptic production and includes areas for material preparation and compounding. Further supporting buildings will have storage spaces, laboratories and offices.

article thumbnail

WHO endorses Gilead’s Yeztugo for HIV prevention

Pharmaceutical Technology

A report by UNAIDS predicts that six million new HIV infections and four million AIDS-related deaths could occur between 2025 and 2029 if US-supported HIV treatment and prevention services collapse. Give your business an edge with our leading industry insights.

article thumbnail

EHDS regulation will depend on strong patient confidence

Pharmaceutical Technology

Communication between European Union (EU) member states is ongoing to finalise the details of the legislation, but at its core, the EHDS will provide a single registry of patient data from across the continent. The regulation came into force in March 2025; however, it has not yet come into application, with this set to happen in March 2029.